ReviewFrontiers in pediatrics2026
Therapeutic approaches for endocrine dysregulation in anorexia nervosa in adolescents.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) is a complex eating disorder characterized by self-induced weight loss, distorted body image, and profound endocrine dysregulation. In adolescents, the illness leads to growth failure, pubertal delay, amenorrhea, and compromised bone mineral accrual. This mini review synthesizes current evidence regarding the pathophysiology and management of endocrine disturbances in adolescents with AN, with a particular focus on therapeutic strategies for growth failure, pubertal arrest, and reduced bone mineral density. Endocrine abnormalities in AN involve adaptive suppression of the hypothalamic-pituitary-gonadal, -adrenal, -thyroid, and -growth hormone axes. Nutritional rehabilitation remains the cornerstone of recovery, as restoration of energy balance normalizes gonadotropin secretion, promotes catch-up growth, and improves bone accrual. Among hormonal options, physiologic transdermal estrogen is currently the only evidence-based strategy for improving bone density and supporting reproductive recovery. Adjunctive therapies such as rhGH, rhIGF-1 or DHEA may hold potential in specific subgroups but require further validation through larger, age-specific randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.